The Pulse
Anthropic Starts In-House Drug Programs After Acquiring Mithril
Anthropic says Claude is supporting its own drug-discovery programs for rare childhood muscular dystrophies after the company acquired one-person startup Mithril Medicine. The October 27 update also details six research partnerships and ear
AI.info Team · Written with AI · fact-checked ·
“We use Claude at the clinical trial stage to analyze proprietary data, create a clinical study plan, and weigh the study’s chance of success.”
Michael Pourdehnad, MD, Senior Vice President, Head of Early Clinical Development, Hematology, Oncology and Cell Therapy
Anthropic is moving beyond providing Claude to drug developers and starting programs of its own. In an update published October 27, the company said it has acquired Mithril Medicine, a one-person startup working on treatments for two rare forms of muscular dystrophy, and that Claude handles much of the scientific and operational work in its in-house efforts.
The announcement also lays out six research partnerships and early results across drug design, manufacturing documentation and trial planning. Anthropic frames the work as both a way to pursue medicines and a practical test of where Claude can help—and where the company needs to improve its models.
Mithril brings Anthropic into its own drug programs
Mithril’s founder, Cody Tranbarger, used Claude to coordinate contracts, logistics and experiments involving 11 external laboratories, as well as other company operations. Anthropic says Mithril moved a possible treatment for one form of muscular dystrophy from an idea to promising results in mice in less than 18 months. Tranbarger is now continuing the work at Anthropic and plans to start several more programs.
The two conditions are LAMA2-related congenital muscular dystrophy and α-dystroglycanopathy. Anthropic says more than 100 bispecific antibodies—molecules designed to bind two targets—are being tested in cell-based experiments. The team aims to prioritize candidates by the end of 2026, with formal drug candidates targeted for 2027; if they hold up, Anthropic says a program could be ready to begin human trials as soon as late 2028.
Those dates are targets, not evidence that a medicine is close to approval. Anthropic describes the work as early and mostly preclinical, meaning it has not reached testing in people. The company’s own account says further testing and development remain ahead.
Six partners test Claude across drug development
Anthropic’s collaborations span BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. The work ranges from designing molecules to preparing manufacturing records and evaluating clinical-trial plans. That breadth reflects Anthropic’s view that delays occur throughout drug development, not only in the first search for a drug candidate.
At BigHat, scientists and an Anthropic researcher used Claude to propose changes to two antibody fragments, then made and tested about 1,010 variants in roughly 10 weeks. The best versions bound their targets more than 10 times as tightly as the originals; one remained in solution at a temperature 18°C higher, while another clumped more than 100 times more slowly. At Generate Biomedicines, a Claude-proposed design for part of CAR T-cell therapy was about 70% shorter than the standard version and performed better in lab tests, according to Anthropic.
Enveda’s work targets paperwork associated with manufacturing and regulatory submissions. In tests involving 1,061 pages of documentation, Claude caught all 11 issues human reviewers had identified and flagged seven more; Anthropic says the process cut review time by 89%, from more than 25 hours to under three. Claude also drafted one regulatory document in four hours, compared with about three months by hand.
Anthropic is testing a new company model
The Column Group is establishing Pleiades, a company intended to use Claude to run more and more complex drug programs than a small team typically can. Its first Claude skill helps assess whether drug targets are worth pursuing and has been evaluated on 45 target-disease pairs. Anthropic presents Pleiades as a test of whether AI can lower not only scientific workloads but also the operational and administrative burden of running a biotechnology company.
Bristol Myers Squibb, meanwhile, is using Claude to assess plans for an early-stage drug in clinical trials and estimate the likelihood of success. The companies plan to expand that work in 2027. Pourdehnad’s statement describes an initial analysis that helped inform decisions that otherwise would take days, while emphasizing that the output supported the company’s assessment rather than replacing it.
Drug candidates remain far from patients
Anthropic’s announcement offers early case studies, not evidence that Claude has produced a medicine ready for human use. Some results involve lab measurements or document review; the Mithril program has reached mouse studies, and the company’s broader portfolio is still mostly preclinical. Human trials, safety testing and regulatory review remain ahead for any program that advances.
The company says the projects also help identify model weaknesses and guide improvements. Its own account describes drug development as a chain of distinct tasks, from choosing a biological target to manufacturing and trial design. The clearest near-term milestone Anthropic names for its in-house muscular-dystrophy work is candidate selection in 2027; its stated late-2028 trial window depends on those candidates continuing to hold up.